Halneuron — Topline data
Fall 2026
Currently, we have enrolled 217 patients and expect top-line data from the trial in the fall of 2026.Source filing
DWTX biotech catalysts & pipeline
DOGWOOD THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
Halneuron — FDA meeting
Late 2026
Submitting our end of Phase 2 summary, manufacturing plans and Phase 3 clinical development plans to FDA towards the end of 2026, assuming favorable outcomes in our ongoing Halneuron ® Phase 2b program.Source filing
Halneuron — Topline data
Nov 2026
The investment comes as Dogwood continues to advance its ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathic Pain ("CINP") trial toward topline data readout in November 2026.Source filing